Developer docs
API playgroundTry for free, no card

Search company profiles

Innovation Pharmaceuticals

Full company profile

uuid0036r7x

Namestring
Innovation Pharmaceuticals
Websiteurl
ipharminc.com
Company typeenum
Private
Founded yearint
2007
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBeverly, United States
HQ citystring
Beverly
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

No data
No data
Differentiator
Functional benefit
Problem solved
No data
Market position
Customer concentration

Classification, Details

No data
API detail

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Innovation Pharmaceuticals

Innovation Pharmaceuticals firmographics

Firmographics
Name
Innovation Pharmaceuticals
Website
https://ipharminc.com
Company type
Private
Founded year
2007
Headcount range
1–10 employees
Ownership category
akta.pro rank

Where Innovation Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Beverly
HQ country
United States
HQ region
North America

Markets served

Innovation Pharmaceuticals technology and API

Technology

API detail

API docs
API detail

Core technology

AI maturity

App detail

Innovation Pharmaceuticals competitors and assessment

Company assessment

Market position

Customer concentration

Innovation Pharmaceuticals social profiles

Digital presence

Innovation Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Innovation Pharmaceuticals leadership team

Management profile

Number of profiles

Innovation Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Innovation Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innovation Pharmaceuticals

When was Innovation Pharmaceuticals founded?

Innovation Pharmaceuticals was founded in 2007. It employs 1 to 10 people.

Where is Innovation Pharmaceuticals based?

Innovation Pharmaceuticals is headquartered in Beverly, United States, in the North America region.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireInnovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal DiseasesInnovation Pharmaceuticals announced USPTO patent grants and an allowance for Brilacidin covering inflammatory bowel diseases and viral infections, with protections through 2036 and 2041. The drug showed clinical remission in ulcerative proctitis trials and beneficial effects in COVID-19 Phase 2 testing. Additional in vivo testing against fungal pathogens is scheduled for Q3 2023.GlobeNewswireInnovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature CommunicationsInnovation Pharmaceuticals announced publication of Brilacidin antifungal research in Nature Communications, showing the peptide potentiates caspofungin against human pathogenic fungi. The compound demonstrated activity in 14 of 19 WHO priority pathogens, and Dr. Gustavo Goldman will join as Scientific Advisor.GlobeNewswireInnovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic ResearchersInnovation Pharmaceuticals announced that NIH/NIAID-affiliated researchers plan new testing of its antifungal candidate Brilacidin after positive findings. Brilacidin showed inhibition against 13 of 19 priority fungal pathogens, including potent activity against C. neoformans, and demonstrated synergy with caspofungin and other antifungals.GlobeNewswireInnovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA SubmissionInnovation Pharmaceuticals visited BeaMed in Israel and confirmed the StingRay laser system is progressing ahead of schedule. The system targets drug-resistant epilepsy and brain tumors, with FDA clearance expected in 2024. Additional submissions for fiber optics and software integration are planned.GlobeNewswireInnovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development AgreementInnovation Pharmaceuticals' BeaMed Technologies and Shina Systems entered a definitive strategic agreement to develop software for the StingRay laser system. The partnership aims to accelerate FDA clearance and commercial deployment of the system for epilepsy and brain tumor surgery. The company expects the agreement to provide strategic advantages and speed up market launch.GlobeNewswireInnovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development AgreementInnovation Pharmaceuticals announced that its minority-owned subsidiary, BT BeaMedical Technologies, entered into a definitive strategic development agreement with Shina Systems Ltd. to create a specialized software suite for the StingRay Laser System. This partnership aims to accelerate the regulatory clearance and commercial deployment of the laser-based platform for treating epilepsy and brain tumors by leveraging Shina's medical imaging expertise.IpharmincInnovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement — Innovation Pharmaceuticals Inc.BT BeaMedical Technologies and Shina Systems Ltd. entered into a definitive strategic development agreement to build an advanced software suite for BeaMed's StingRay Laser System, which is used for treating epilepsy and brain tumors. This partnership leverages Shina's medical imaging expertise to accelerate the regulatory clearance and commercial deployment of the laser-based thermal ablation technology. Innovation Pharmaceuticals, which holds a minority ownership stake in BeaMed, views this collaboration as a key step toward FDA submission and product launch.BioSpaceInnovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development AgreementBT BeaMedical Technologies and Shina Systems Ltd. have entered into a definitive strategic development agreement to create an advanced software suite for BeaMed's StingRay Laser System. Innovation Pharmaceuticals, which holds a minority ownership stake in BT BeaMedical Technologies, is the parent company notifying the market of this partnership. The collaboration aims to accelerate regulatory clearance and commercial deployment for the laser-based platform used in epilepsy and brain tumor surgeries.GlobeNewswireInnovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal KeratitisInnovation Pharmaceuticals reported new in vivo data showing Brilacidin reduced fungal burden and disease severity in a murine fungal keratitis model, with almost no viable fungus in treated corneas. The company plans to screen Brilacidin with NIH/NIAID to further characterize its broad-spectrum antifungal activity.